SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-22-002406
Filing Date
2022-02-24
Accepted
2022-02-24 16:09:32
Documents
13
Period of Report
2022-02-24
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT awh-8k_022422.htm   iXBRL 8-K 34069
2 PRESS RELEASE ISSUED BY ASPIRA WOMEN'S HEALTH INC. ex99-1.htm EX-99.1 12282
  Complete submission text file 0001387131-22-002406.txt   226484

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT awh-20220224.xsd EX-101.SCH 3030
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT awh-20220224_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT awh-20220224_pre.xml EX-101.PRE 22594
7 EXTRACTED XBRL INSTANCE DOCUMENT awh-8k_022422_htm.xml XML 3741
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 22670996
SIC: 2835 In Vitro & In Vivo Diagnostic Substances